文献速递胸部肿瘤放疗放疗物理与技术

以放射性肺炎为终点评估质子治疗器官特异性相对生物效应

Evaluation of organ-specific relative biological effectiveness of proton therapy using radiation-induced pneumonitis as an endpoint.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-12-01

该回顾性研究纳入两项临床试验中270例NSCLC患者(光子治疗134例、质子治疗136例),以RP2+为终点评估质子治疗器官特异性RBE。两种方法估计的RBE分别为1.10–1.35(均值1.28)和1.13–1.33(均值1.23),均持续高于常规假设的1.1。

要点

  • 质子治疗肺的RBE以RP2+为终点持续高于1.1。
  • 光子/质子剂量比法RBE为1.10–1.35,均值1.28。
  • LET增强LKB模型RBE为1.13–1.33,均值1.23。

核心结论

  • 质子治疗以RP2+为终点的RBE存在变异且高于常规1.1假设,治疗计划中需考虑可变RBE。

研究设计与样本

  • 回顾性研究,分析两项临床试验共270例NSCLC患者,其中光子治疗134例、质子治疗136例。
  • 获取全部患者物理剂量,对质子治疗患者计算剂量平均LET(LETd)。
  • 采用LKB模型预测RP2+发生率,并以光子/质子等RP2+发生率剂量比及LET增强LKB模型两种方法估计RBE。

主要发现

  • 质子治疗患者RP2+的估计RBE存在变异且持续超过1.1。
  • 光子/质子剂量比模型估计RBE为1.10–1.35,平均1.28。
  • LET增强LKB模型估计RBE为1.13–1.33,平均1.23。

关键数值与推荐

  • 终点为RP2+(2级及以上放射性肺炎)。
  • 常规假设RBE为1.1。
  • 光子/质子剂量比法RBE范围1.10–1.35,均值1.28。
  • LET增强LKB模型RBE范围1.13–1.33,均值1.23。

临床怎么用

  • 质子治疗NSCLC计划评估肺毒性时,不宜仅采用固定RBE 1.1,应考虑可变RBE。
  • 可结合LETd信息与LKB模型评估RP2+风险。

局限性

  • 为回顾性研究,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Proton therapy has become widely used for non-small cell lung cancer (NSCLC) due to its ability to spare normal tissue. However, the commonly assumed relative biological effectiveness (RBE) of 1.1 may underestimate the therapy's true biological effects on lung, potentially leading to a higher than expected incidence of radiation-induced pneumonitis (RP). In this retrospective study, we evaluated the variability of organ-specific RBE of proton therapy using RP grade 2 or higher (RP2+) as an endpoint. MATERIALS AND METHODS: Data from 270 NSCLC patients across two clinical trials were analyzed, with 134 given photon therapy and 136 given proton therapy. The physical dose was obtained for all patients, and the dose-averaged linear energy transfer (LETd) was computed for proton therapy recipients. The Lyman-Kutcher-Burman (LKB) model was used to predict RP2+ incidence. RBE was determined using 1) the ratio of the photon dose to the proton dose achieved the same RP2+ incidence and 2) an LET-based RBE estimation derived from the LET-enhanced LKB model. RESULTS: The estimated RBE for RP2+ in proton therapy recipients was variable and consistently exceeded 1.1. The RBE estimated from the photon-to-proton dose ratio model between 1.10 and 1.35, with an average of 1.28. While the LET-enhanced LKB model yielded an RBE range of 1.13 to 1.33, with an average of 1.23. CONCLUSION: This study demonstrated that the RBE of proton therapy for RP2+ is variable and higher than the conventional 1.1 assumption, emphasizing the need to account for variable RBE in treatment planning.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liao L, Xu T, Chen M, et al. Evaluation of organ-specific relative biological effectiveness of proton therapy using radiation-induced pneumonitis as an endpoint. Clin Transl Radiat Oncol. 2025. PMID: 41445933. doi:10.1016/j.ctro.2025.101089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。